1. Introduction {#sec1-genes-11-00469}
===============

The skin forms an essential barrier against the environment. In humans, the soles of the feet and the palms of the hands are covered by the specially structured palmoplantar epidermis, which has to bear the strongest mechanical forces of the entire skin. Genodermatoses characterized by altered structural and junctional proteins of these specialized regions comprise the palmoplantar keratodermas (PPK), a diverse group of inherited disorders collectively characterized by excessive or abnormal thickening of the palmoplantar skin. Variants in at least 32 genes have been shown to cause different forms of isolated or syndromic PPK in humans ([Table 1](#genes-11-00469-t001){ref-type="table"}) \[[@B1-genes-11-00469],[@B2-genes-11-00469]\].

Footpad hyperkeratosis in dogs is a genetically heterogenous group of inherited diseases corresponding to human PPK. So far, causative genetic variants for two different forms of canine footpad hyperkeratosis have been reported. Hereditary footpad hyperkeratosis (HFH) in Irish Terriers and Kromfohrländer dogs is caused by a variant in the *FAM83G* gene \[[@B36-genes-11-00469]\] encoding a protein involved in BMP and WNT signaling \[[@B37-genes-11-00469],[@B38-genes-11-00469],[@B39-genes-11-00469]\]. The syndromic HFH phenotype is characterized by an orthokeratotic hyperplasia of the footpad epidermis in combination with an irregular hair morphology. *FAM83G* variants have also been described in human patients with PPK and exuberant scalp hair \[[@B12-genes-11-00469]\] and the wooly mouse mutant \[[@B40-genes-11-00469]\]. A *KRT16* frameshift variant has been reported in Dogues de Bordeaux with focal nonepidermolytic footpad hyperkatosis \[[@B41-genes-11-00469]\]. Interestingly, this disease is inherited as an autosomal recessive trait, while the human forms of *KRT16*-associated focal nonepidermolytic PPK typically are inherited as autosomal dominant traits \[[@B25-genes-11-00469],[@B26-genes-11-00469]\].

This study was initiated after an owner reported a juvenile male Rottweiler dog suffering from footpad hyperkeratosis. The goal of the study was to characterize the clinical and histopathological phenotype and to identify a possible underlying causative genetic defect.

2. Materials and Methods {#sec2-genes-11-00469}
========================

2.1. Ethics Statement {#sec2dot1-genes-11-00469}
---------------------

All animal experiments were performed according to local regulations. The dog in this study is privately owned and was examined with the consent of the owner. The \"Cantonal Committee for Animal Experiments\" approved the collection of blood samples (Canton of Bern; permit 75/16).

2.2. Animal Selection {#sec2dot2-genes-11-00469}
---------------------

A male Rottweiler dog with footpad hyperkeratosis was investigated. Footpad biopsies were collected at initial presentation to rule out infectious and inflammatory causes of hyperkeratosis. The clinical presentation was inconsistent with other causes of secondary hyperkeratosis. An EDTA blood sample was collected for genomic DNA isolation. Additionally, we used 15 blood samples from other Rottweilers, which had been donated to the Vetsuisse Biobank. They represented population controls without reports of footpad hyperkeratosis. The photo of the control Rottweiler, shown in [Figure 1](#genes-11-00469-f001){ref-type="fig"}B, represents a stock photo from the University of Pennsylvania (UPENN) veterinary hospital. This dog was not genotyped. The biopsy of the control dog, shown in [Figure 2](#genes-11-00469-f002){ref-type="fig"}A, originates from a six-month-old healthy Beagle that was part of another IACUC-approved study at the UPENN School of Veterinary Medicine.

2.3. Histopathological Examinations {#sec2dot3-genes-11-00469}
-----------------------------------

Two 6 mm punch biopsies from the footpads were obtained under general anesthesia. The samples were fixed in 10% neutral buffered formalin and routinely processed, including staining with hematoxylin and eosin.

2.4. DNA Extraction {#sec2dot4-genes-11-00469}
-------------------

Genomic DNA was isolated from EDTA blood with the Maxwell RSC Whole Blood Kit using a Maxwell RSC instrument (Promega, Dübendorf, Switzerland).

2.5. Whole-Genome Sequencing {#sec2dot5-genes-11-00469}
----------------------------

An Illumina TruSeq PCR-free DNA library with \~500 bp insert size of the affected dog (RO015) was prepared. We collected 329 million 2 × 150 bp paired-end reads on a NovaSeq 6000 instrument (37x coverage). Mapping and alignment were performed as described \[[@B42-genes-11-00469]\]. The sequence data were deposited under the study accession PRJEB16012 and the sample accession SAMEA6249501 at the European Nucleotide Archive.

2.6. Variant Calling {#sec2dot6-genes-11-00469}
--------------------

Variant calling was performed using GATK HaplotypeCaller \[[@B43-genes-11-00469]\] in gVCF mode as described \[[@B42-genes-11-00469]\]. To predict the functional effects of the called variants, SnpEff \[[@B44-genes-11-00469]\] software together with NCBI annotation release 105 for the CanFam3.1 genome reference assembly was used. For variant filtering we used 655 control genomes ([Table S1](#app1-genes-11-00469){ref-type="app"}).

2.7. Gene Analysis {#sec2dot7-genes-11-00469}
------------------

We used the CanFam3.1 dog reference genome assembly and NCBI annotation release 105. Numbering within the canine *DSG1* gene corresponds to the NCBI RefSeq accession numbers NM_001002939.1 (mRNA) and NP_001002939.1 (protein).

2.8. Sanger Sequencing {#sec2dot8-genes-11-00469}
----------------------

The *DSG1*:c.2541_2545delGGGCT variant was genotyped by direct Sanger sequencing of PCR amplicons. A 402 bp (or 397 bp in case of the mutant allele) PCR product was amplified from genomic DNA using AmpliTaqGold360Mastermix (Thermo Fisher Scientific, Waltham, MA, USA) together with primers 5'-GAG CAC TGA ACC GAT TTG CC -3' (Primer F) and 5'- GGC ATA GTC AAA GAG GTG GGT-3' (Primer R). After treatment with exonuclease I and alkaline phosphatase, amplicons were sequenced on an ABI 3730 DNA Analyzer (Thermo Fisher Scientific). Sanger sequences were analyzed using the Sequencher 5.1 software (GeneCodes, Ann Arbor, MI, USA).

3. Results {#sec3-genes-11-00469}
==========

3.1. Clinical Examination {#sec3dot1-genes-11-00469}
-------------------------

A six-month-old male intact Rottweiler dog presented for evaluation of thick, rapidly growing footpads and discomfort (shifting stance, unwilling to stand for long periods). An unusual appearance of the pads (described as "dryness") had been first noted by the owners when the dog was obtained at eight weeks of age. At the time of the initial presentation, the patient was otherwise healthy with no other systemic or dermatologic signs. On examination, all pads on all feet were markedly thickened by dense mounds of adherent keratin ([Figure 1](#genes-11-00469-f001){ref-type="fig"}). The digital pads and metatarsal/metacarpal pads were the most severely affected. Fissures and mobile keratin ridges were present along the edges of the pads. There was mild diffuse scale over the trunk, which was considered to be within normal limits.

Regular application of moisturizers (urea), keratolytic (propylene glycol), and keratoplastic agents (salicylic acid/sulfur) and regular home trimming was recommended. The patient was unable to tolerate oral retinoids (isotretinoin). Initially, physical trimming of footpads under general anesthesia was performed every 4--6 months. However, the frequency by which this was required increased over time, and by the third year of life, it was performed every 8--10 weeks. To address significant discomfort, the patient was also started on gabapentin and codeine for pain control.

Additionally, between 8--12 months of age, the patient developed mild nonseasonal pruritus and recurrent ear infections. The patient was placed on an isoxazoline (Bravecto®) for parasite control. A 10-week strict hydrolyzed protein (Royal Canin Ultamino®) diet trial was performed without improvement, and the patient was presumptively diagnosed with atopic dermatitis. At one year of age, the patient was started on 0.5 mg/kg Oclacitinib (Apoquel®) for control of pruritus.

Despite control of pruritus, the patient continued to develop recurrent ear infections and intermittent episodes of bacterial skin infection. Superficial bacterial infections developed most frequently in areas of heavy wear (elbows, lateral hocks) but were also found occasionally on the trunk, neck, and glabrous areas. At sites of infection, hyperkeratotic plaques with superficial crusting were noted ([Figure S1](#app1-genes-11-00469){ref-type="app"}). Infections were managed with topical antiseptics and systemic culture-based antibiotics when indicated.

3.2. Histopathological Findings {#sec3dot2-genes-11-00469}
-------------------------------

Histologically, the stratum corneum was markedly expanded by villous projections of orthokeratotic hyperkeratosis. The subtending granular layer of the epidermis was mildly hyperplastic. The samples had no significant inflammation ([Figure 2](#genes-11-00469-f002){ref-type="fig"}).

3.3. Genetic Analysis {#sec3dot3-genes-11-00469}
---------------------

We sequenced the genome of the affected dog and searched for homozygous and heterozygous variants in 32 known candidate genes ([Table 1](#genes-11-00469-t001){ref-type="table"}) that were not present in the genome sequences of 647 control dogs and 8 wolves ([Table 2](#genes-11-00469-t002){ref-type="table"}, [Table S2](#app1-genes-11-00469){ref-type="app"}).

This analysis identified a single homozygous private protein-changing variant in *DSG1*, a known candidate gene for palmoplantar keratoderma in humans \[[@B9-genes-11-00469]\]. The variant, a 5 bp deletion, can be designated as Chr7:58,163,636_58,163,640del5 (CanFam3.1 assembly). It is a frameshift variant, NM_001002939.1:c.2541_2545delGGGCT, predicted to truncate 207 amino acids from the C-terminus of the wildtype DSG1 protein, NP_001002939.1:p.(Gly848Trpfs\*2). We did not investigate whether any mutant protein is expressed or whether the premature stop codon caused by the frameshift deletion leads to nonsense-mediated decay of the transcript.

We confirmed the presence of the 5 bp coding deletion in *DSG1* by Sanger sequencing and genotyped 15 control Rottweiler dogs. The case was homozygous for the mutant allele, while none of the 15 control dogs carried this allele ([Figure 3](#genes-11-00469-f003){ref-type="fig"}).

4. Discussion {#sec4-genes-11-00469}
=============

In this study, we identified a homozygous *DSG1*:c.2541_2545delGGGCT frameshift variant in a Rottweiler dog with severe footpad hyperkeratosis. *DSG1* encodes desmoglein 1, a calcium-binding transmembrane glycoprotein of the cadherin family. Desmoglein 1 represents a major component of desmosomes that mediates cell--cell adhesion between keratinocytes in the upper layers of the epidermis \[[@B45-genes-11-00469]\]. Intact desmosomes are essential to maintain the skin barrier function \[[@B45-genes-11-00469]\]. Desmoglein 1 also represents the major autoantigen in human pemphigus foliaceus \[[@B46-genes-11-00469]\].

Variants in human *DSG1* cause striate palmoplantar keratoderma I (SPPK1). It is interesting to note that SPKK1 in humans is an autosomal dominant phenotype with the pathogenic variants being present in a heterozygous state in affected individuals \[[@B9-genes-11-00469],[@B47-genes-11-00469]\]. In humans, SPKK1 is caused by haploinsufficiency of desmoglein 1 \[[@B9-genes-11-00469],[@B47-genes-11-00469]\]. The investigated dog of our study was homozygous for a presumed null allele of *DSG1* and unlikely to express any functional desmoglein 1. In humans, a rare syndromic form of PPK referred to as SAM syndrome has been reported in patients with biallelic *DSG1* loss-of-function variants \[[@B48-genes-11-00469]\]. Subsequent studies of further human patients with biallelic *DSG1* variants confirmed the dermatitis and multiple allergies but failed to replicate the reported malabsorption and metabolic wasting \[[@B49-genes-11-00469],[@B50-genes-11-00469]\]. The clinical presentation of the affected dog in our study, including the development of atopic dermatitis and hyperkeratotic lesions at sites of bacterial skin infection, resembles the phenotype of human SAM syndrome patients without the metabolic wasting, similar to what has been reported in several human cases \[[@B49-genes-11-00469],[@B50-genes-11-00469]\].

The histopathological alterations in the footpad skin of the affected Rottweiler were comparable to the changes seen in footpad hyperkeratosis of *FAM83G* mutant Irish Terriers and Kromfohrländer dogs \[[@B36-genes-11-00469]\] and *KRT16* mutant Dogues de Bordeaux \[[@B41-genes-11-00469]\]. Thus, the histopathology cannot predict the specific underlying genetic defect. The clinical phenotype of the studied Rottweiler was more severe than in the previously described canine inherited footpad hyperkeratoses \[[@B36-genes-11-00469],[@B41-genes-11-00469]\] and required periodical trimming of the excessively hyperkeratotic footpads. In addition to the severely affected footpads, the *DSG1* mutant Rottweiler also had an allergic skin disease and was prone to repeated bacterial skin infections. Such features have not been reported in *FAM83G* mutant Irish Terriers or Kromfohrländer dogs \[[@B36-genes-11-00469]\] or in *KRT16* mutant Dogues de Bordeaux \[[@B41-genes-11-00469]\].

Unfortunately, we did not have access to the parents of the affected dog or any other heterozygous dog. It would be interesting to investigate whether heterozygous dogs have completely normal footpads or whether they exhibit a mild phenotype that might go unnoticed by their owners.

In summary, we identified a Rottweiler dog with severe footpad hyperkeratosis that clinically and genetically resembled human SAM syndrome without metabolic wasting. To the best of our knowledge, this dog represents the first nonhuman patient with a spontaneous *DSG1* gene defect.

The authors are grateful to the dog owner who donated samples and participated in the study. We thank Eva Andrist, Nathalie Besuchet Schmutz, Sabrina Schenk, and Daniela Steiner for expert technical assistance; the Next Generation Sequencing Platform of the University of Bern for performing the high-throughput sequencing experiments; and the Interfaculty Bioinformatics Unit of the University of Bern for providing high-performance computing infrastructure.

The following are available online at <https://www.mdpi.com/2073-4425/11/4/469/s1>, Figure S1: Hyperkeratotic plaque at the elbow of the affected dog. Table S1: Accession numbers of 648 dog and 8 wolf genome sequences; Table S2: Private variants in the sequenced Rottweiler with footpad hyperkeratosis.
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![Clinical phenotype at six months of age. (**A**) Marked expansion of the footpads by thick projections of dense keratin in the affected Rottweiler. The adjacent haired skin appears unaffected on this image. (**B**) Footpads of a normal six-month-old control Rottweiler.](genes-11-00469-g001){#genes-11-00469-f001}

![Histopathological phenotype of footpad skin. (**A**) Footpad skin of a normal six-month-old control dog. (**B**) In a biopsy taken from the affected dog at six months of age, a dense proliferation of the stratum corneum (outermost anucleated layer of the skin) markedly expands the epidermis. The stratum corneum is arranged in papillated villous projections of dense keratin. (**C**) Higher magnification of the stratum granulosum and stratum corneum of the affected dog shows an expansion of the granular cell layer.](genes-11-00469-g002){#genes-11-00469-f002}

![Details of the *DSG1*:c.2541_2545delGGGCT variant. Representative electropherograms of a control and the affected dog are shown. The amino acid translations of the wild-type and mutant alleles are indicated.](genes-11-00469-g003){#genes-11-00469-f003}

genes-11-00469-t001_Table 1

###### 

Overview of genetic causes of human palmoplantar keratodermas (PPK).

  Gene         Phenotype                                                                 Inheritance ^a^   Ref.
  ------------ ------------------------------------------------------------------------- ----------------- -------------------------------------------------
  *AAGAB*      Palmoplantar keratoderma, punctate type IA; PPKP1A                        AD                \[[@B3-genes-11-00469],[@B4-genes-11-00469]\]
  *AQP5*       Palmoplantar keratoderma, Bothnian type                                   AD                \[[@B5-genes-11-00469]\]
  *CARD5*      Pityriasis rubra pilaris                                                  AD                \[[@B6-genes-11-00469]\]
  *COL14A1*    Palmoplantar keratoderma, punctate type IB; PPKP1B                        AD                \[[@B7-genes-11-00469]\]
  *CTSC*       Papillon-Lefevre syndrome                                                 AR                \[[@B8-genes-11-00469]\]
  *DSG1*       Palmoplantar keratoderma I, striate, focal, or diffuse; PPKS1             AD                \[[@B9-genes-11-00469]\]
  *DSP*        Palmoplantar keratoderma II, striate, focal, or diffuse; PPKS2            AD                \[[@B10-genes-11-00469]\]
  *ENPP1*      Cole disease                                                              AD                \[[@B11-genes-11-00469]\]
  *FAM83G*     Palmoplantar keratoderma and exuberant scalp hair.                        AR                \[[@B12-genes-11-00469]\]
  *GJA1*       Palmoplantar keratoderma with congenital alopecia                         AD                \[[@B13-genes-11-00469]\]
  *GJB2*       Keratoderma, palmoplantar, with deafness                                  AD                \[[@B14-genes-11-00469]\]
  *GJB3*       Erythrokeratodermia variabilis et progressiva 1                           AD or AR          \[[@B15-genes-11-00469]\]
  *GJB4*       Erythrokeratodermia variabilis et progressiva 2                           AD                \[[@B16-genes-11-00469]\]
  *GJB6*       Ectodermal dysplasia 2, Clouston type                                     AD                \[[@B17-genes-11-00469]\]
  *JUP*        Naxos disease                                                             AR                \[[@B18-genes-11-00469]\]
  *KANK2*      Palmoplantar keratoderma and woolly hair                                  AR                \[[@B19-genes-11-00469]\]
  *KRT1*       Palmoplantar keratoderma, epidermolytic or nonepidermolytic               AD                \[[@B20-genes-11-00469]\]
  *KRT6A*      Pachyonychia congenita 3                                                  AD                \[[@B21-genes-11-00469]\]
  *KRT6B*      Pachyonychia congenita 4                                                  AD                \[[@B22-genes-11-00469]\]
  *KRT6C*      Palmoplantar keratoderma, nonepidermolytic, focal or diffuse              AD                \[[@B23-genes-11-00469]\]
  *KRT9*       Palmoplantar keratoderma, epidermolytic                                   AD                \[[@B24-genes-11-00469]\]
  *KRT16*      Palmoplantar keratoderma, nonepidermolytic, focal 1, FNEPPK1              AD                \[[@B25-genes-11-00469],[@B26-genes-11-00469]\]
  *KRT17*      Pachyonychia congenita 2                                                  AD                \[[@B26-genes-11-00469]\]
  *LOR*        Vohwinkel syndrome with ichthyosis                                        AD                \[[@B27-genes-11-00469]\]
  *POMP*       Keratosis linearis with ichthyosis congenita and sclerosing keratoderma   AR                \[[@B28-genes-11-00469]\]
  *SASH1*      Cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma     AR                \[[@B29-genes-11-00469]\]
  *SERPINB7*   Palmoplantar keratoderma, Nagashima type; PPKN                            AR                \[[@B30-genes-11-00469]\]
  *SLURP1*     Meleda disease                                                            AR                \[[@B31-genes-11-00469]\]
  *TAT*        Tyrosinemia, type II                                                      AR                \[[@B32-genes-11-00469]\]
  *TGM1*       Ichthyosis, congenital, autosomal recessive 1                             AR                \[[@B33-genes-11-00469]\]
  *TRPV3*      Palmoplantar keratoderma, nonepidermolytic, focal 2; FNEPPK2              AD                \[[@B34-genes-11-00469]\]
  *WNT10A*     Schöpf--Schulz--Passarge syndrome                                         AR                \[[@B35-genes-11-00469]\]

^a^ AD: autosomal dominant; AR: autosomal recessive.

genes-11-00469-t002_Table 2

###### 

Results of variant filtering in the affected Rottweiler dog against 655 control genomes.

  Filtering Step                              Homozygous Variants   Heterozygous Variants
  ------------------------------------------- --------------------- -----------------------
  All variants in the affected Rottweiler     3,310,269             2,516,875
  Private variants                            842                   3290
  Protein-changing private variants           4                     25
  Private variants in known candidate genes   1                     0
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